High-level Group on the Security of Supply of Medical Radioisotopes

Fourth mandate (2015-2017)

The fourth mandate of the HLG-MR will allow for an extension of its work in the field of security of supply of medical radioisotopes. The work will address specific issues affecting the full implementation of the HLG-MR policy approach, such as full-cost recovery and isotope reimbursement. The HLG-MR will continue to work towards increasing the long-term security of supply by maintaining transparency on global developments, communicating with the supply chain and end-users, evaluating progress towards implementation and providing additional information and analysis, where necessary. The group will meet twice a year to share information and to discuss ongoing policy issues.

The broad deliverables of the group during its fourth mandate are:

  • Carrying out studies related to the security of supply, e.g. updating the global 99Mo/99mTc medium- and long-term demand and capacity forecast.
  • Evaluating progress towards the implementation of the HLG-MR policy approach through a fourth self-assessment by the global supply chain.
  • Closer engagement with downstream supply chain participants (e.g. 99mTc generator manufacturers, nuclear pharmacy operators, nuclear medicine and other associated healthcare professionals and healthcare policy makers) to understand the impact of economic forces throughout the entire supply chain.
  • Re-examining the six HLG-MR policy principles, in particular, those where market participants have reported having significant implementation challenges and consider if adjustment is required and additional policy principles appropriate.
  • Sharing of information on the status of the 99Mo/99mTc market and regular reporting on developments within the market, to increase transparency and encourage consistency in approach, implementation and communication.
  • Communicating the need to implement the HLG-MR policy approach to governments and supply chain participants, including working more closely with nuclear medicine and associated healthcare professionals and healthcare policy makers.
  • Actions to support the implementation approach, where appropriate and feasible.
  • Reporting regularly on HLG-MR actions to governments and other major stakeholders.

Last reviewed: 12 August 2015

Top